Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas

18 Aug 2018

Abstract excerpt

CMTM6, a previously uncharacterized protein, was identified as a critical regulator of PD-L1, which is reported as an immune checkpoint inhibitor, to modulate the T cell activities both in vitro and in vivo of other tumors. However, the role of CMTM6 has so far remained unclear in glioma. To investigate the role of CMTM6 in gliomas, we analyzed the transcriptome level, genomic profiles and its relationship with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Chemokine receptors and signaling
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30131308
DOI: 10.1016/j.ebiom.2018.08.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomasPMID 30131308Read ↗

Prognostic Implications of Pan-cancer CMTM6 Expression and Its Relationship With the Immune MicroenvironmentSemantic proximity Read ↗

Comprehensive analysis of m6A/m5C/m1A-related gene expression, immune infiltration, and sensitivity of antineoplastic drugs in gliomaSemantic proximity Read ↗

TRIM6: An Upregulated Biomarker with Prognostic Significance and Immune Correlations in GliomasSemantic proximity Read ↗

High PRMT6 expression Associated With Prognosis and Immune Infiltration in GliomaSemantic proximity Read ↗

High Expression of PRMT6 Associated With Prognosis and Immune Infiltration in GliomaSemantic proximity Read ↗

High Level of METTL7B Indicates Poor Prognosis of Patients and Is Related to Immunity in GliomaSemantic proximity Read ↗

Characterization of METTL7B to Evaluate TME and Predict Prognosis by Integrative Analysis of Multi-Omics Data in GliomaSemantic proximity Read ↗

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironmentSemantic proximity Read ↗

Prognostic value and drug sensitivity of FBXL6 in gliomaSemantic proximity Read ↗

Comprehensive Analysis of Expression and Prognostic Value of MS4As in GliomaSemantic proximity Read ↗

Prognostic Value of CMTM6 Expression in Breast CancerSemantic proximity Read ↗

Multi-omics analyses of CD276 in pan-cancer reveals its clinical prognostic value in glioblastoma and other major cancer typesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.